Overview

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children
Phase:
Phase 2
Details
Lead Sponsor:
Alcon Research
Treatments:
Olopatadine Hydrochloride